Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sales & Earnings In Brief

This article was originally published in The Tan Sheet

Executive Summary

McNeil Q2 sales: Second quarter U.S. sales growth of 19% in OTC unit fueled by increased promotional activities for adult Tylenol, pediatric Motrin brands, J&J says during July 16 analysts call. McNeil domestic sales reached $359 mil. in the period, offsetting a 7% decline in international sales to $65 mil. Worldwide revenues for women's health products up 5% to $321 mil. in the quarter, contributing to 7.8% global sales advance to $1.65 bil. for the overall J&J Consumer segment, which includes skin care and baby care products in addition to McNeil and women's health. Also contributing to the gain wereNeutrogena, Clean & Clear skin care products, Viactiv chewable calcium supplements, J&J notes...
Advertisement
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS094310

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel